For this research, a total of 28 subjects were imaged with a variety of
imaging modalities, including standard
imaging with computed tomography, magnetic resonance
imaging and molecular bone scan (SI); PET with a
common radiotracer called fluorodeoxyglucose (FDG - PET); and PET with computed tomography and the agent Zr - 89 IAB2M (IAB2M PET / CT) assessed in escalated doses.